06/16/2022
•2024Viewpoint
Visby Medical to Present Poster at the Julius Schacter Chlamydia Conference
Offering a high-quality scientific meeting covering all aspects in the field of chlamydia research, this symposium provides an excellent opportunity for specialists and trainees in sexual health, HIV medicine, public health, microbiology, epidemiology and behavioral science to share their ideas and experiences.
Julius Schachter Fifteenth International Symposium on Human Chlamydial Infections
June 19-June 24, 2022
The Historic Menger Hotel
204 Alamo Plaza
San Antonio,TX 78205
Offering a high-quality scientific meeting covering all aspects in the field of chlamydia research, this symposium provides an excellent opportunity for specialists and trainees in sexual health, HIV medicine, public health, microbiology, epidemiology and behavioral science to share their ideas and experiences. Participants will be able to discuss the latest advances and progress in the field from the varied viewpoints of clinical practice and research in chlamydial biology, laboratory detection, public health epidemiology, and sexual behavior.
Teresa Abraham will be presenting in a Tuesday evening poster session.
Learn more about the Visby Medical Sexual Health Test
Read more articles & insights
CARB-X awards funding to Visby Medical for gonorrhea, antibiotic susceptibility test
The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced today that it will award biotechnology company Visby Medical of San Jose, California, up to $1.8 million
Visby Medical™ Receives FDA Clearance and CLIA Waiver for second Generation Sexual Health Test for Women
Visby Medical™ announced today that it has received 510(k) clearance and was granted a CLIA waiver from the FDA for its 2nd generation point of
Visby Medical Receives FDA Emergency Use Authorization for Respiratory Health Test for Use in CLIA Waived Settings
Visby Medical announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for its Respiratory Health point of
Visby Medical Expands Series E Round to Over $135 Million
Visby Medical announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for its Respiratory Health point of
